Use: Labeled indications
- INDICATIONS AND USAGE Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus.
Full indications and usage US FDA label
INDICATIONS AND USAGE Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.
Contraindications
CONTRAINDICATIONS Hypertension; toxemia; pregnancy; and hypersensitivity.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Intramuscularly 1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours. Intravenously 1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See WARNINGS.) Orally One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Film-coated tablet: 125 mcg
- Solution for injection: 200 mcg/mL
Registered products in the Philippines
15 products registered with the Food and Drug Administration (FDA) Philippines list Methylergometrine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products15
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BiometrineMethylergometrine maleate | 125 mcg Film-Coated TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Euro-Health Care Exponents, Inc. | DR-XY39750 | Jul 11, 2031 | |
CethergoMethylergometrine Maleate | 200 mcg/mL Solution for Injection (IM/ IV)Type I Amber Glass Ampoule x 1 mL (Box of 50’s) | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | LORDLA PHARMA SALES | DR-XY23015-B | Jul 10, 2028 | |
ErgeMethylergometrine Maleate | 125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 50's and 100's) | Rx | JAYSON PHARMACEUTICALS LTD.Bangladesh | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC. | DRP-4222-02 | Apr 20, 2027 | |
ErgojenMethylergometrine Maleate | 125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Vamsler Phils. Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-3587-03 | Nov 12, 2027 | |
ErgometMethylergometrine Maleate | 200 mcg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL wrapped in Aluminum Foil Pouch (Box of 5's and 10's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading, Inc. | DRP-8424 | Sep 12, 2029 | |
ErgonMethylergometrine Maleate | 125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 50’S and 100’s) | Rx | Jayson Pharmaceuticals Ltd.Bangladesh | Aglobal Care, Inc. | DRP-4222 | Apr 20, 2027 | |
ErgotecMethylergometrine maleate | 125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Aldril Pharmaceuticals, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-3587-01 | Nov 12, 2027 | |
MergoMethylergometrine Maleate | 125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | JAYSON PHARMACEUTICALS LTD.Bangladesh | REGIMED PHARMACEUTICAL DISTRIBUTORImporter: AGLOBAL CARE, INC. | DRP-4222-01 | Apr 20, 2027 | |
MergotMethylergometrine maleate | 125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-3587 | Nov 12, 2027 | |
MergotMethylergometrine Maleate | 200 mcg/mL Solution for Injection (IM/IV)Amber Glass Ampoule x 1 mL in a Clear Plastic Tray x 10's (Box of 10's and 50's) | Rx | Daewon Pharm. Co., Ltd.Republic of Korea | Solvang Pharmaceuticals, Inc.Importer: D.B. Manix International, Inc. | DRP-2604 | May 29, 2031 | |
MergotMethylergometrine Maleate | 200 mcg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL Wrapped in Aluminum Foil Pouch Box of 5's and Box of 10's | Rx | Geofman PharmaceuticalsPakistan | Solvang Pharmaceuticals, Inc.Importer: Sahar International Trading, Inc. | DRP-8424-01 | Sep 12, 2029 | |
Saph-memMethylergometrine maleate | 200 mcg/mL Solution for Injection (I.M./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 5's, 10's, and 50's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-10688 | Nov 8, 2031 | |
SaphgometrineMethylergometrine maleate | 125 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x (Box of 100's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma Trading, Inc. | DRP-13722 | Mar 31, 2028 | |
UterginMethylergometrine (as maleate) | 200 mcg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 1 mL in Transparent Plastic Tray (Box of 10's) | Rx | Ciron Drugs & Pharmaceuticals Pvt. Ltd.India | Phil. Pharmawealth, Inc.Trader: Oboi Laboratories | DR-XY38420 | Aug 31, 2030 | |
ZemetrinMethylergometrine maleate | 125 mcg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Janamed CorporationTrader: Solvang Pharmaceuticals, Inc. | DRP-3587-04 | Nov 12, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS General This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V administration is considered essential as a lifesaving measure, Methergine (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.
Intra-arterial or periarterial injection should be strictly avoided. Caution should be exercised in presence of impaired hepatic or renal function. Breast-feeding Mothers should not breast-feed during treatment with Methergine. Milk secreted during this period should be discarded. Methergine may produce adverse effects in the breast-feeding infant.
Methergine may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of Methergine before initiating or resuming breast feeding. Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm.
Medication errors Inadvertent administration of Methergine to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as respiratory depression, convulsions, cyanosis and oliguria have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required.
Methergine has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, Methergine injection should be stored separately from medications intended for neonatal administration.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution.
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine.
Beta-blockers Caution should be exercised when Methergine is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothan and methoxyfluran may reduce the oxytocic potency of Methergine. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs.
No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
Less potent CYP 3A4 inhibitors should be administered with caution.
These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.
CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. Rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. 1 There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product.
Postmarketing Experience The following adverse drug reactions have been derived from post-marketing experience with Methergine via spontaneous case reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.
Nervous system disorders Cerebrovascular accident, paraesthesia Cardiac disorders Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Category C: Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE).
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Mothers should not breast-feed during treatment with Methergine and at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded.
Pharmacokinetics
Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.
The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.
Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%.
Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver. Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg.
When given intramuscularly, the extent of absorption of Methergine solution was about 25% greater than the tablet. The volume of distribution (Vd ss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
A delayed gastrointestinal absorption (T max about 3 hours) of Methergine tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Methylergometrine 200 mcg/mL, 1 mL Ampule | ₱11.12–₱70.00Reference ₱13.79 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Methergine · Lupin Pharmaceuticals,Inc. [US FDA-approved label, version 3, March 20, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f04ca06-fe52-46d6-96cd-2e77ef6fa36f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .